COMMUNIQUÉS West-GlobeNewswire

-
Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK
02/09/2024 -
Myocene Helps the French Handball Team
02/09/2024 -
MYOCENE AU SERVICE DE L'ÉQUIPE DE FRANCE DE HANDBALL
02/09/2024 -
PCI Biotech: Employee share option scheme
02/09/2024 -
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
02/09/2024 -
CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des personnes avec une sclérose en plaques...
02/09/2024 -
Claritas HealthTech Furthers its Capabilities in Urology with ReDisys™, a Computer Aided Detection Software for Kidney Cancer in CT Scans
02/09/2024 -
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
02/09/2024 -
Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000 Site Members
01/09/2024 -
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
01/09/2024 -
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
01/09/2024 -
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
01/09/2024 -
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
31/08/2024 -
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
31/08/2024 -
Avricore Grants Options
31/08/2024 -
Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024
30/08/2024 -
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30/08/2024 -
Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus
30/08/2024 -
Receipt of Nasdaq Delisting Determination - Plans to Appeal
30/08/2024
Pages